ECM
ADCT icon

Evergreen Capital Management’s ADC Therapeutics ADCT Stock Holding History

Evergreen Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,000
Closed -$18.3K – 875
2023
Q4 		$18.3K Hold
11,000
– – ﹤0.01% 841
2023
Q3 		$9.87K Hold
11,000
– – ﹤0.01% 792
2023
Q2 		$23.6K Buy
+11,000
New +$24.7K ﹤0.01% 798

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Evergreen Capital Management's ADCT Position: Q1 2024 in Review

Evergreen Capital Management sold out of ADC Therapeutics (ADCT) in Q1 2024, closing a stake of 11,000 shares — an estimated $18.3K sold.

Evergreen Capital Management first reported a position in ADCT in Q2 2023 and held it in 3 quarters. The position peaked at $23.6K in Q2 2023. 36 funds tracked by Wall St. Rank hold ADCT as of Q1 2024.

  • Evergreen Capital Management reported no remaining ADC Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Evergreen Capital Management sold 11,000 ADC Therapeutics shares in Q1 2024, an estimated $18.3K.
  • Evergreen Capital Management first reported a position in ADC Therapeutics in Q2 2023 and held it in 3 quarters.
  • Evergreen Capital Management's ADC Therapeutics position peaked at $23.6K in Q2 2023.
  • 36 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2024.

Based on Evergreen Capital Management's 13F filing for Q1 2024, filed 15 May 2024.